

Methyl aminolevulinate 160mg/g cream (Metvix^o) (No. 50/03)
Galderma (UK) Ltd

Summary of Recommendation

10 November, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a resubmission.

Accepted for use within NHS Scotland.

The evidence of efficacy for Metvix for the treatment of thin or non-hyperkeratotic and non-pigmented actinic keratosis on the face and scalp is not strong. The health economic evidence is incomplete, though it suggests similar costs to the alternative treatment (cryotherapy). However, Metvix appears to have a place for treatment of those patients when other therapies are considered less appropriate and should be delivered by a dermatologist experienced in this therapy.

Professor David H Lawson
Chairman